Shares of Derma Sciences Inc. (NASDAQ:DSCI) saw unusually-strong trading volume on Monday . Approximately 149,600 shares were traded during trading, an increase of 144% from the previous session’s volume of 61,414 shares.The stock last traded at $4.72 and had previously closed at $4.84.

A number of equities analysts have issued reports on DSCI shares. Zacks Investment Research lowered Derma Sciences from a “buy” rating to a “hold” rating in a research note on Tuesday, July 12th. TheStreet raised Derma Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday, August 9th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $7.35.

The company’s market capitalization is $133.60 million. The company’s 50 day moving average price is $4.82 and its 200 day moving average price is $3.91.

Derma Sciences (NASDAQ:DSCI) last announced its quarterly earnings results on Tuesday, August 9th. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.16. The business had revenue of $22.20 million for the quarter, compared to the consensus estimate of $22.40 million. Analysts forecast that Derma Sciences Inc. will post ($0.04) earnings per share for the current fiscal year.

Derma Sciences, Inc (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.